Document is current

Article History

Accepted: 20 June 2023

First Online: 24 August 2023

Declarations

:

: Funding for medical writing was sponsored by Samsung Bioepis Co., Ltd.

: H.C. received consultancy/advisory boards fees, lecturing/research support/education support from MSD, Lilly, AbbVie, Pfizzer, Gebro, BMS, Roche, Sanofi, Novartis, UCB, Celgene, Amgen, Biogen, Khern, Galapagos, Fresenius, and Chiesi. D.Y. declares no conflict of interest to disclose. F.C. received consultancy/lecturing/research support/education support from AbbVie, Amgen, AstraZeneca, Biogen, Celltrion, Galapagos, Gilead, GlaxoSmithKline, Janssen, MSD, Nestle Health Sciences, Norgine, Pfizer, Pharmacosmos, Samsung Bioepis, Shield Therapeutics, Takeda, and Vifor. Y.B. has received consulting/advisory board fees from AbbVie, Amgen, Biogaran, Biogen, Boehringer Ingelheim, Celltrion, Ferring, Fresenius Kabi, Gilead, Hospira, Iterative Scopes, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Roche, Sandoz, Sanofi, Shire, Takeda, Tillotts, and UCB. A.A. has received consulting/advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, and Takeda; speaker’s fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; research support from MSD, Takeda, Pfizer, and Biogen. J.K. is an employee of Samsung Bioepis.

: This review is based on previously conducted studies and does not contain any studies with human participants or animals performed by the author.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: HC, DY, JRFC, UB, AA, DT and JK contributed to the conception, drafts, and final version of this article, and gave approval of the version to be published.